Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6465 - 6472 of 12032 results
BART Derails App User's Data-Collection Class Action
December 15, 2017| News
Final tax bill gives muni market the gift of continued PABs
December 15, 2017| News
Pulling the Plug on Terrorism: A Constitutional Solution to Online Mass-Violence Manuals
December 14, 2017| News
Mintz’s Health Care Enforcement Defense Group Publishes New Qui Tam Update
December 14, 2017| Blog| Viewpoint
Cosmetic Companies Must Plan For New Regulation
December 14, 2017| News
NELF bestows Cabot Award on health care industry’s Brent Henry
December 14, 2017| News
Think Tank: For Companies Fighting Knockoffs, the USITC Is a Holiday Gift
December 14, 2017| News
Massachusetts Appeals Court Upholds Liability Insurer’s Contractual Right to Settle
December 14, 2017| Advisory| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|